Brief: Novartis - Data Shows 58% Lower Risk Of Psa Progression With Pluvicto In Prostate Cancer
18/05/2026 06:48
May 18 (Reuters) - NOVARTIS AG NOVN.S Said on Sunday: New Psmaddition Data Show 58% Lower Risk Of Psa Progression With Pluvicto In Metastatic Hormone-Sensitive Prostate Cancer Source text for Eikon: ID:nTUABS98WP Further company coverage: [NOVN.S] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600))
Recent news on Novartis AG
See all newsBrief: Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu)
Swiss stocks - Factors to watch on June 12
Swiss pharma hub Basel frets over population cap threat
Novartis says rare muscle disease drug shows promise in early trial
Live Markets: Europe at half-time: countdown to the ECB's 'insurance hike'